Skip to main content
Top
Published in: International Journal of Hematology 2/2019

01-08-2019 | Myelodysplastic Syndrome | Progress in Hematology

Epigenetic abnormalities and therapies for hematological malignancies

Author: Toshio Kitamura

Published in: International Journal of Hematology | Issue 2/2019

Login to get access

Excerpt

The 9th JSH International Symposium was held in Kyoto on July 26–27, 2018. The meeting focused on “Epigenetic abnormalities and therapies of hematological malignancies,” and included numerous engaging and informative talks by prominent speakers from Asia, Europe, and the United States. As in the past, we organized ASH-JSH and EHA-JSH Joint Symposia, as well as two simultaneous sessions with Asian scholars. In addition to the 19 talks by invited speakers from abroad and 11 by Japanese presenters, 67 poster presentations were accepted, including three that were selected for oral presentation.
Metadata
Title
Epigenetic abnormalities and therapies for hematological malignancies
Author
Toshio Kitamura
Publication date
01-08-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02691-1

Other articles of this Issue 2/2019

International Journal of Hematology 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine